Edition:
India

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

67.81USD
19 Jan 2018
Change (% chg)

$-3.56 (-4.99%)
Prev Close
$71.37
Open
$69.84
Day's High
$71.67
Day's Low
$66.50
Volume
1,478,321
Avg. Vol
729,163
52-wk High
$74.32
52-wk Low
$19.08

Chart for

About

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to... (more)

Overall

Beta: --
Market Cap(Mil.): $4,869.33
Shares Outstanding(Mil.): 111.66
Dividend: --
Yield (%): --

Financials

Celgene in talks to buy Juno Therapeutics - WSJ

Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading.

17 Jan 2018

UPDATE 1-Celgene in talks to buy Juno Therapeutics -WSJ

Jan 16 Celgene Corp is in talks to buy Juno Therapeutics Inc, which is working on an experimental gene therapy drug to treat cancer, the Wall Street Journal reported on Tuesday, citing sources familiar with the matter. (http://on.wsj.com/2EMlysO)

17 Jan 2018

Celgene in talks to buy Juno Therapeutics - WSJ

Jan 16 Celgene Corp is in talks to buy Juno Therapeutics Inc, the Wall Street Journal reported, citing sources familiar with the matter. (http://on.wsj.com/2EMlysO)

17 Jan 2018

BRIEF-Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​

* CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​

17 Jan 2018

BRIEF-Juno Therapeutics And Thermo Fisher Scientific Announce CAR T Manufacturing Partnership

* JUNO THERAPEUTICS AND THERMO FISHER SCIENTIFIC ANNOUNCE CAR T MANUFACTURING PARTNERSHIP

20 Dec 2017

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION

06 Dec 2017

BRIEF-Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​

* Juno Therapeutics reports third quarter 2017 financial results

02 Nov 2017

BRIEF-Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform

* Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform

18 Oct 2017

BRIEF-Juno Therapeutics prices $250 million follow-on offering

* Juno Therapeutics- Announced pricing of its follow-on public offering of 6.1 million shares of its common stock at a price to public of $41.00 per share Source text for Eikon: Further company coverage:

22 Sep 2017

BRIEF-Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​

* Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​ Source text for Eikon: Further company coverage:

21 Sep 2017

Earnings vs. Estimates